Aim To estimate the prevalence of both cardiometabolic and other co‐morbidities in patients
with COVID‐19, and to estimate the increased risk of severity of disease and mortality in …

Introduction On February 11, 2020 WHO designated the name “COVID-19” for the disease
caused by “severe acute respiratory syndrome coronavirus 2”(SARS-CoV-2), a novel virus …

Background and aims This meta-analysis aims to highlight the impact of cardio-metabolic
comorbidities on COVID-19 severity and mortality. Methods A thorough search on major …

Aim: Several studies reported the accompaniment of severe COVID-19 with comorbidities.
However, there is not a systematic evaluation of all aspects of this association. Therefore …

Background Estimating the risk of pre-existing comorbidities on coronavirus disease 2019
(COVID-19) mortality may promote the importance of targeting populations at risk to improve …

Background: The pandemic of Coronavirus Disease 2019 (COVID-19) has been a threat to
global health. In the US, the Centers for Disease Control and Prevention (CDC) has listed 12 …

ABSTRACT SARS-CoV-2 has caused a worldwide pandemic that began with an outbreak of
pneumonia cases in the Hubei province of China. Knowledge of those most at risk is integral …

Background and aims Currently there is limited knowledge on medical comorbidities and
COVID-19; we conducted a systematic review and meta-analysis to evaluate the impact of …

Background An outbreak of coronavirus disease 2019 (COVID-19) occurred in Wuhan,
China; the epidemic is more widespread than initially estimated, with cases now confirmed …

Currently, the number of patients with coronavirus disease 2019 (COVID-19) has increased
rapidly, but relationship between comorbidity and patients with COVID-19 still not clear. The …